81 results about "Cognitive decline" patented technology

The application discloses application of T1R3 agonist sucralose in relieving Alzheimer's disease and related cognitive impairment, and aims at brain glucose metabolism disorder and cognitive decline problem, and the application takes sucralose as the only pharmaceutical active ingredient, corrects brain glucose metabolism disorder through targeting brain astrocyte sweet taste receptor T1R3, and then treats and relieves neurodegenerative diseases. The application is proved by animal experiments that cognitive dysfunction of AD model mice can be improved in a full range of molecular mechanisms, cell functions, tissue metabolisms and whole behavior, and a variety of dosage forms and medication strategies can be selected, and the application has good in-vivo safety and clinical transformation potential.

The application belongs to the field of food processing and biomedical technology, and discloses a preparation method of a salty taste enhancing peptide-naringenin compound and application of the compound in improving cognitive decline. The compound is prepared by compounding salty taste enhancing peptides from soft-shelled turtle eggs and naringenin at a ratio of 20-150:1 (w:w). The preparation process comprises the following steps: soft-shelled turtle egg enzymolysis, ultrafiltration, freeze-drying to obtain salty taste enhancing peptides, mixing the salty taste enhancing peptides with a naringenin solution, concentration, and freeze-drying. The compound has good stability, salty taste enhancing and antioxidant activities, can reduce the use of salt and maintain salty taste. The compound can improve cognitive decline and anxiety caused by aging and diabetes, improve autonomous activity, memory and social skills, strengthen physical fitness, protect nerve cells and skeletal muscles, maintain brain tissue health, and can be applied to the preparation of related preparations for improving cognitive decline.

An object of a system according to an embodiment is to propose an appropriate countermeasure when there is a suspicion of cognitive decline or Alzheimer's disease.SOLUTION: A system according to an embodiment includes a generation AI, a conversation analysis unit, a suggestion unit, and a share unit. The generated AI interacts with the user. The conversation analysis unit analyzes the conversation content generated by the generation AI. The suggestion unit suggests a BRAIN AGE: Train Your Brain in Minutes a Day!, a quiz, or an appropriate physical exercise when cognitive decline or Alzheimer's disease is suspected on the basis of a result of the analysis by the conversation analysis unit. The sharing unit aggregates a history of conversation contents as a summary or an analysis result, and shares the history with a specific person.SELECTED DRAWING: Figure 1

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

The present application belongs to the technical field of medical health, and specifically relates to a type 2 diabetes cognitive function decline prediction system and method. The present application can timely find the cognitive function decline trend by real-time monitoring and analyzing the cognitive function impairment of type 2 diabetes patients, thereby providing a scientific basis for clinical diagnosis and treatment. Through accurate image processing and data analysis, the present application can effectively predict the safety boundary of cognitive function decline and provide personalized prevention and intervention measures for patients. In addition, the present application can accurately assess the level of cognitive function decline according to the diffusion tensor of cognitive function impairment, thereby providing an important reference for doctors to develop treatment plans, and ultimately helping to improve the quality of life of type 2 diabetes patients and reduce the risk of cognitive impairment.

A system and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in a subject based on speech samples. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitively declining patients to generate an ensemble classifier including a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine learning classifier configured to generate a component output that identifies the sample data as corresponding to a normal patient or a cognitively declining patient. The machine learning classifiers are generated based on a subset of available features. The ensemble module receives the component outputs from all of the component classifiers and generates an ensemble output that identifies the sample data as corresponding to a normal patient or a cognitively declining patient based on the component outputs.

The invention discloses a heteroaromatic compound as well as a preparation method and application thereof. The invention provides a compound as shown in a formula I, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The novel aromatic heterocyclic compound is a selective dopamine D1 / D5 ligand, has good affinity and selectivity to a target spot, and can be used for treating D1 / D5-mediated (or D1 / D5-related) disorders including schizophrenia, cognitive impairment, age-related cognitive decline, dementia, Parkinson's disease and the like.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The invention relates to the technical field of individualized cognition, in particular to an individualized cognitive decline risk prediction method and system based on multi-mode data fusion. According to the method, multi-modal longitudinal evidence-based data is integrated on the basis of a group-level pathology law, a multi-scale causal link map capable of reflecting the complete period of cognitive decline is formed, pathology time axis alignment and individualized feature normalization are achieved, the dynamic pathology process of individual specificity can be captured, and the accuracy of the pathology process is improved. By fitting individual exclusive multi-scale causal parameters and constructing a time sequence cascade digital twinborn body, forward causal simulation can be executed on multiple time scales, a cognitive decline core driving path is directly revealed, and individual risk quantification and intervention targets are generated. Detection of early hidden pathological signals, dynamic modeling of individual heterogeneity and comprehensive analysis of a multi-channel pathological mechanism are achieved, the ultra-early prediction precision of cognitive decline and individualized intervention suitability are remarkably improved, and a full-period prediction system capable of being iteratively optimized continuously is formed.

The system notifies family members and the attending physician of changes in the game performance achieved by the person receiving care via a data terminal, allowing the family and the attending physician to share information about the person receiving care's condition, and also to share this information with care support staff at the facility, thereby facilitating the provision of the best possible care. [Solution] In a monitoring system that supports the monitoring of a person receiving care, the first server device 4 manages the history of scores obtained by an intelligent game application installed on a first data terminal 10-1 etc. operated by a person receiving care at a care facility 100, and works in conjunction with a second data terminal 2-1 etc. operated by a caregiver to dynamically grasp the state of cognitive decline of the person receiving care, and is characterized by a configuration that supports a service that provides thorough monitoring of the person receiving care by creating a program to improve the symptoms of the person receiving care.

An exemplary device, according to the present disclosure, provides a housing, an AR lens, a projector, a memory, and a control system. The control system and memory determine when the user is confused. The control system then provides for projecting a reorientation graphic via the projector directed at the AR lens. In some implementations, the reorientation graphic provides real time information and reminders to a user as they proceed through life. The exemplary device enables a user to maintain greater independence and a more normal lifestyle with the assistance of the reorientation graphic.

The invention relates to a neural stem cell exosome miR-106b compound and application of the neural stem cell exosome miR-106b compound in treatment of neurodegenerative diseases. It is found for the first time that the miR-106b-carrying neural stem cell exosome compound can effectively reduce damage to neurons and synapses and relieve neuroinflammation in in-vitro and in-vivo experiments. Animal experiment results show that in-vivo injection of the compound or the miR-106b simulant can be used as a treatment means for inhibiting neuroinflammation, and cognitive function decline related to neurodegenerative diseases can be resisted.

A vector for use in treating cognitive decline and / or memory deficits in a subject in need thereof includes an expression cassette that includes a nucleic acid encoding asprosin and / or an analogue thereof, operably linked to one or more regulatory elements that promote expression of the asprosin and / or an analogue thereof coding sequence, wherein the one or more regulatory elements include a nucleic acid promoter, a polyadenylation (poly(A)) tail signal, and / or posttranscriptional regulatory element.

The invention relates to the technical field of data processing, and discloses a mild cognitive impairment detection system based on multi-level data, and the system comprises a terminal device which is used for collecting physiological monitoring data, clinical narrative data and multi-modal test data of a user; the data processing module is used for performing interference identification and information purification on the multi-modal test data to generate a purified cognitive response matrix; the cognitive evaluation module is used for performing cognitive ability decoupling and group benchmarking based on the purified cognitive response matrix and outputting an individual ability level; and the closed-loop management module is used for constructing a longitudinal decline slope model based on a score sequence of individual historical multiple evaluations and carrying out risk early warning and intervention recommendation. According to the method, passive disease screening of cognitive health management is converted into an active, personalized and continuous risk monitoring and intervention process, and a powerful technical tool is provided for delaying cognitive decline.

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The invention provides a quick response type nutrient composition for a cognitive load scene. The quick response type nutrient composition is prepared from the following raw materials in parts by weight: 400 to 600 parts of L-alpha-choline alfoscerate, 0.1 to 0.4 part of pyrroloquinoline quinone disodium salt, 4 to 6 parts of blueberry anthocyanin, 4 to 6 parts of gamma-aminobutyric acid, 4 to 6 parts of L-lysine and 4 to 6 parts of L-arginine. The invention further provides a preparation method and application of the quick response type nutrient composition for the cognitive load scene. Through the synergistic effect of the six components, a nerve cell energy metabolism-neurotransmitter balance-oxidation protection three-channel synergistic mechanism is formed, through the multi-target-point synergistic effect, the prepared nutrient composition has the multiple effects of improving the cognitive decline symptom, rapidly relieving cognitive fatigue, improving the thinking agility and reducing the error rate; the method is especially suitable for a high-intensity cognitive load scene. The invention belongs to the technical field of food processing.

To provide a bath agent for improving cognitive functions or preventing cognitive decline.SOLUTION: The present invention provides a bath agent for improving cognitive functions or preventing cognitive decline which contains 1,8-cineole and is foamable.SELECTED DRAWING: Figure 1

The present invention relates to treating neurodegeneration (e.g., a neurodegenerative disorder), enhancing cognitive function, delaying or reducing cognitive decline, enhancing the metabolism, and / or improving memory in patients in need thereof, e.g., patients diagnosed with a neurodegenerative disorder or displaying one or more symptoms of a neurodegenerative disorder (e.g., declining cognitive function) by administering Pla2g2f to a subject or increasing expression of Pla2g2f in a cell of a subject.

The invention discloses a preparation method and application of ganoderma lucidum outer vesicles without sporocarp waste sources. The ganoderma lucidum external vesicles are used for preparing medicines for treating ischemic cerebral apoplexy sequelae, and can improve core symptoms such as dyskinesia (including limb paralysis, imbalance and gait abnormity), cognitive decline and the like after apoplexy. The spore-free sporocarp waste sourced ganoderma lucidum outer vesicles are prepared from spore-free sporocarp waste which is completely released by spores after a ganoderma lucidum powder spraying period through raw material pretreatment, differential centrifugation, tangential flow concentration and filter membrane filtration. According to the preparation method, the waste is used as a raw material to prepare the high-value medical outer vesicle, green circulation of agricultural waste-high-added-value medical raw materials is achieved, the ganoderma lucidum outer vesicle can effectively penetrate through the blood-brain barrier, brain-targeted delivery is achieved, and the problems that traditional ganoderma lucidum active ingredients are low in blood-brain barrier penetration rate and poor in blood-brain barrier penetration rate are solved. The effective treatment concentration in the brain tissue is difficult to achieve, and the traditional drug delivery bottleneck is broken through.

The invention belongs to the technical field of health monitoring, and particularly relates to a senile dementia risk home monitoring method based on multi-modal behavior analysis, which comprises the following specific steps: monitoring human body postures in real time, analyzing repeated actions, synchronously early warning abnormal movement, and carrying out voice interaction operation through a built-in AI dialogue terminal; performing behavior, emotion and physiology correlation modeling, executing cognitive decline dynamic evaluation through cognitive function self-test, and judging a risk level according to an analysis and evaluation result; executing a multi-level early warning mechanism based on the risk level information, and automatically taking corresponding emergency measures; the threshold value is dynamically calibrated by integrating user habit data, a closed-loop feedback mechanism is designed to realize false alarm suppression, and a monthly health report is synchronously generated to assist a doctor in adjusting an intervention scheme. The problems that in a traditional monitoring mode, tiny behavior changes are difficult to capture, rescue is delayed due to subjective evaluation hysteresis and passive response, the screening frequency is low, and the scene is limited can be solved.

The present invention relates to a composition for preventing or treating aging containing an extract of Cordyceps sinensis from edible insects as an active ingredient. Since the composition of the present invention exhibits an effect of preventing or treating aging, it can be effectively used to prevent or improve various diseases and health problems caused by aging. In particular, the composition of the present invention can be usefully used to prevent or treat aging-related diseases such as sarcopenia, cognitive decline, cardiovascular disease, cancer, and diabetes. The extract of Cordyceps sinensis from edible insects according to the present invention can be obtained by extracting Cordyceps sinensis fruiting bodies, obtained by culturing Cordyceps sinensis fungi on edible insects such as crickets, mealworm larvae, white-spotted flower beetle larvae, rhinoceros beetle larvae, and grasshoppers, using solvents such as water, ethanol, and methanol. The composition of the present invention can be prepared in various forms, such as food compositions, health functional food compositions, pharmaceutical compositions, and cosmetic compositions.

The disclosure relates to compositions and methods for diagnosing, stratifying, prognosing, treating and preventing and cognitive impairment, including Alzheimer's Disease, based on the identification of disease-associated metabolic transitions.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

The invention relates to a probiotic cocktail medical food composition and application thereof in delaying the progress of Parkinson's disease. The composition comprises (a) at least one probiotic with a neuroprotection or metabolism regulation function; (b) a functional amino acid combination, wherein the functional amino acid combination comprises four or more kinds of essential amino acid. The composition can be prepared into a medical food formula, is suitable for improving or relieving pathological changes such as dyskinesia, cognitive degeneration, inflammatory response and granulocyte function imbalance related to the Parkinson's disease, and can be used for daily nutrition supplement and disease progress delay of patients with the Parkinson's disease or high-risk groups.

The invention discloses an application of miRNA in diagnosis of cognitive function decline induced by hypoxia stress, the miRNA is miR-3473h-p3, the miRNA has good diagnostic efficiency, accuracy, sensitivity and specificity for diagnosis of cognitive function decline induced by hypoxia stress, can be used in effective diagnosis of cognitive function decline induced by hypoxia stress, and has good application prospects in diagnosis of cognitive function decline induced by hypoxia stress. The invention provides a brand new thought and strategy for research and development of diagnosis products related to hypoxia stress induced cognitive function decline, and has wide application prospects and important conversion significance in the technical field of diagnosis of hypoxia stress induced cognitive function decline.

Methods for preventing or slowing the progression of cognitive impairment or preventing the development or reducing the rate of cognitive decline. Methods for slowing the volumetric atrophy or reduction of a subregion of the medial temporal lobe. Methods for slowing the volumetric atrophy or reduction of the entorhinal cortex (ERC). Methods for slowing the volumetric atrophy or reduction of the transentorhinal cortex (BA35). The methods comprise administering to an APOE4 non-carrier subject one or more of levetiracetam, brivaracetam or seletracetam, or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising levetiracetam, brivaracetam or seletracetam or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The disclosure relates to methods for treating cognitive decline or selecting subjects for treatment with an anti-semaphorin-4D antibody using the subject's Mini-Mental State Exam (MMSE) score and / or an equivalent cognitive assessment test score as a patient biomarker.

A mobile device system includes a mobile device having a housing and one or more buttons disposed on the housing, and a case configured to receive the mobile device. The protective case comprises an outer surface and an inner surface having indentations corresponding to the one or more buttons of the mobile device. The indentations are configured to prevent a user from pressing the one or more buttons when the mobile device is inserted into the protective case. The protective case allows access to ports of the mobile device while preventing access to the buttons, providing protection against both intentional and accidental button presses for users with cognitive decline.

To provide pharmaceutical compositions for the diagnosis, prevention, and / or treatment of age-related cognitive decline, including pathological neurodegeneration. [Solution] A pharmaceutical composition comprising the following components: a therapeutically effective amount of one or more of the following: a CD103 inhibitor, a perforin 1 inhibitor, and an IFNγ inhibitor, wherein the CD103 inhibitor is an anti-CD103 antibody, selected from the group consisting of PE anti-human CD103 antibody derived from clone Ber-ACT8, mouse anti-human CD103 monoclonal antibody (mAb) derived from clone 2G5.1, humanized antibody of 2G5.1, OX-62, humanized antibody of OX-62, anti-mouse CD103 mAb derived from clone 2E7, humanized antibody of 2E7, and paxilin; the perforin 1 inhibitor is selected from the group consisting of diarylthiophene and GSK2126458; and the IFNγ inhibitor is selected from the group consisting of mesopram and locagramide.